127 related articles for article (PubMed ID: 26649873)
1. Comment on: "A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood".
Li GF; Gu X; Yu G; Zhao SY; Zheng QS
Clin Pharmacokinet; 2016 Jan; 55(1):133-7. PubMed ID: 26649873
[No Abstract] [Full Text] [Related]
2. Author's Reply to Zheng et al.: A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows.
Rasool MF; Khalil F; Läer S
Clin Pharmacokinet; 2016 Jan; 55(1):139-41. PubMed ID: 26649872
[No Abstract] [Full Text] [Related]
3. A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows.
Rasool MF; Khalil F; Läer S
Clin Pharmacokinet; 2015 Sep; 54(9):943-62. PubMed ID: 25773479
[TBL] [Abstract][Full Text] [Related]
4. Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach.
Rasool MF; Khalil F; Läer S
Drug Metab Dispos; 2016 Jul; 44(7):1103-15. PubMed ID: 27068272
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach.
Rasool MF; Khalil F; Läer S
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):383-396. PubMed ID: 27313074
[TBL] [Abstract][Full Text] [Related]
6. Carvedilol: a review of its use in chronic heart failure.
Keating GM; Jarvis B
Drugs; 2003; 63(16):1697-741. PubMed ID: 12904089
[TBL] [Abstract][Full Text] [Related]
7. Carvedilol for heart failure.
Med Lett Drugs Ther; 1997 Sep; 39(1010):89-91. PubMed ID: 9323960
[No Abstract] [Full Text] [Related]
8. Carvedilol.
Frishman WH
Indian Heart J; 1999; 51(3):325-32. PubMed ID: 10624077
[No Abstract] [Full Text] [Related]
9. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure.
Tenero DM; Henderson LS; Campanile AM; Baidoo CA; Boyle D
Am J Cardiol; 2006 Oct; 98(7A):27L-31L. PubMed ID: 17023229
[TBL] [Abstract][Full Text] [Related]
10. [Carvedilol].
Antepohl W; Herzig S; Böhm M
Dtsch Med Wochenschr; 1997 Jun; 122(25-26):833-4. PubMed ID: 9244672
[No Abstract] [Full Text] [Related]
11. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic characteristics of beta-blockers: when differences may matter.
Metra M; Dei Cas L; Cleland JG
J Card Fail; 2006 Apr; 12(3):177-81. PubMed ID: 16624681
[No Abstract] [Full Text] [Related]
13. Renal and cardiac function during alpha1-beta-blockade in congestive heart failure.
Heitmann M; Davidsen U; Stokholm KH; Rasmussen K; Burchardt H; Petersen EB
Scand J Clin Lab Invest; 2002; 62(2):97-104. PubMed ID: 12004934
[TBL] [Abstract][Full Text] [Related]
14. Carvedilol: use in chronic heart failure.
Doughty RN; White HD
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
[TBL] [Abstract][Full Text] [Related]
16. Antifibrotic Effects of Carvedilol and Impact of Liver Fibrosis on Carvedilol Pharmacokinetics in a Rat model.
El-Demerdash E; Abdel-Sattar SA; El-Bakly WM; Mohamed EA
Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):767-779. PubMed ID: 28012025
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure.
Takayanagi R; Fujito K; Kimura K; Yamada Y
Biol Pharm Bull; 2017; 40(6):837-843. PubMed ID: 28566627
[TBL] [Abstract][Full Text] [Related]
18. Controlled-release carvedilol.
Carter NJ; Keating GM
Am J Cardiovasc Drugs; 2008; 8(4):271-82. PubMed ID: 18690761
[No Abstract] [Full Text] [Related]
19. Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol.
Bertera FM; Di Verniero CA; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharmacol Toxicol Methods; 2009; 59(1):13-20. PubMed ID: 18973819
[TBL] [Abstract][Full Text] [Related]
20. Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET.
McBride BF; White CM
J Clin Pharmacol; 2005 Jan; 45(1):6-24. PubMed ID: 15601801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
